Tema Etfs LLC Makes New $846,000 Investment in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Tema Etfs LLC acquired a new stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 25,735 shares of the biopharmaceutical company's stock, valued at approximately $846,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Envestnet Asset Management Inc. grew its holdings in Agios Pharmaceuticals by 3.3% during the 4th quarter. Envestnet Asset Management Inc. now owns 24,805 shares of the biopharmaceutical company's stock valued at $815,000 after buying an additional 795 shares in the last quarter. Venturi Wealth Management LLC bought a new stake in Agios Pharmaceuticals in the fourth quarter worth $33,000. Franklin Resources Inc. bought a new position in shares of Agios Pharmaceuticals in the 3rd quarter valued at about $1,499,000. Vanguard Group Inc. raised its holdings in Agios Pharmaceuticals by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company's stock valued at $185,045,000 after buying an additional 85,339 shares during the period. Finally, Northern Trust Corp grew its holdings in Agios Pharmaceuticals by 0.9% during the 4th quarter. Northern Trust Corp now owns 595,480 shares of the biopharmaceutical company's stock valued at $19,567,000 after purchasing an additional 5,372 shares during the last quarter.

Analysts Set New Price Targets

Several research firms have issued reports on AGIO. Scotiabank lowered their price objective on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a research report on Friday, May 2nd. HC Wainwright started coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They set a "buy" rating and a $58.00 price objective for the company. Finally, Wall Street Zen downgraded Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday. One analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $56.00.

Insider Activity at Agios Pharmaceuticals

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of the stock in a transaction dated Thursday, April 10th. The stock was sold at an average price of $25.90, for a total transaction of $194,172.30. Following the transaction, the director now owns 149,220 shares of the company's stock, valued at approximately $3,864,798. This represents a 4.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.30% of the stock is owned by insiders.

Agios Pharmaceuticals Trading Down 0.4%

AGIO stock traded down $0.13 during mid-day trading on Friday, reaching $29.47. The company's stock had a trading volume of 84,600 shares, compared to its average volume of 676,146. The company's 50 day moving average is $28.69 and its two-hundred day moving average is $36.27. Agios Pharmaceuticals, Inc. has a fifty-two week low of $23.42 and a fifty-two week high of $62.58. The stock has a market cap of $1.71 billion, a PE ratio of 2.60 and a beta of 0.77.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, topping analysts' consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. The firm had revenue of $8.73 million for the quarter, compared to the consensus estimate of $9.86 million. On average, analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.